TagsInvestigational

Tag: Investigational

Healthcare

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

Ravindra Soni - May 21, 2026 0

Healthcare

Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)

Ravindra Soni - May 5, 2026 0

Healthcare

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease

Ravindra Soni - February 10, 2026 0

Automobile

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

Ravindra Soni - February 5, 2024 0

Most Read

HID joins FIDO Alliance Board, appoints Sean Dyon as Primary Delegate

October 14, 2026

Swan Realty launches Bodhi luxury residential project in Bengaluru’s Jayanagar

October 14, 2026

Tata Elxsi Q2 FY27 revenue rises 15% YoY to Rs 1,055.7 crore

October 14, 2026

CRIF-SIDBI report: Small business credit portfolio hits ₹50.9 lakh crore in June 2026

October 14, 2026

EDITOR PICKS

HID joins FIDO Alliance Board, appoints Sean Dyon as Primary Delegate

October 14, 2026

Swan Realty launches Bodhi luxury residential project in Bengaluru’s Jayanagar

October 14, 2026

Tata Elxsi Q2 FY27 revenue rises 15% YoY to Rs 1,055.7 crore

October 14, 2026

POPULAR POSTS

HID joins FIDO Alliance Board, appoints Sean Dyon as Primary Delegate

October 14, 2026

Swan Realty launches Bodhi luxury residential project in Bengaluru’s Jayanagar

October 14, 2026

Tata Elxsi Q2 FY27 revenue rises 15% YoY to Rs 1,055.7 crore

October 14, 2026

ABOUT US

BusinessFortnight (businessfortnight.com) is an Indian digital news and media platform that covers business, economy, banking, insurance, real estate, automobiles, aviation, and hospitality news

Contact us: editorbusinessfortnight(@)gmail.com

© BusinessFortnight.com. All Rights Reserved.